Explore the Agenda

8:00 am Check In & Light Breakfast

8:50 am Chair’s Opening Remarks

Vice President - Translational Medicine, BridgeBio Oncology Therapeutics

Transforming Complex Spatial Omics & Digital Pathology Data into Actionable Biomedical Conclusions to Drive Therapeutic Development

9:00 am Progressing Spatial Biology & Digital Pathology into the Clinic to Achieve Unique Insights & Meaningful Clinical Outcomes

Executive Director - Translational Pathology, Amgen
  • Validating novel technologies and demonstrating their value as tools for clinical progression
  • Navigating the regulatory landscape of bringing spatial omics & digital pathology into clinical studies
  • Clinical data to highlight the unique benefit of employing spatial biology and digital pathology for patient selection, biomarker validation and toxicity testing

9:30 am Transforming Complex Spatial Omics Data into Actionable Biomedical Conclusions with Standardized Analysis & AI Capabilities

Executive Director, Amgen
  • Defining consistent methodologies for data interpretation and reporting across diverse spatial technologies
  • Using AI tools to interpret complex spatial data, identify disease signatures and accelerate biomarker validation
  • Unifying tools, teams, and processes to transform complex spatial omics datasets into clinically actionable results

10:00 am Morning Break & Speed Networking

Network with your peers on this exclusive session to exchange your ideas and generating meaningful industry connections and collaborations with other spatial omics and digital pathology experts

Translating Spatial Biology & Computational Pathology into the Clinic by Navigating Regulatory Hurdles & Validating Novel Technologies

11:00 am Facilitating Novel Clinical Insights through the Adoption of Spatial Omics & Digital Pathology in Translational Workflows

Senior Scientist, Zymeworks
  •  Evaluating emerging technologies to demonstrate their clinical utility
  • Charting a clear regulatory course for bringing spatial omics and digital pathology into clinical research
  • Presenting clinical evidence that showcases the added value of spatial biology and digital pathology in across therapeutic pipelines

11:30 am Integrating Spatial Biology & Digital Pathology Into Clinical Workflows to Enable Differentiated Insights & Improve Clinical Outcomes

Senior Director, Translational Medicine, Anaptys Biosciences
  • Establishing functional workflows across spatial biology and digital pathology teams to drive collaboration and maximize efficiency of analysis
  • Tackling the regulatory complexities that arise when transitioning spatial omics and digital pathology from discovery to clinical application
  • Sharing clinical outcomes that reveal the real-world advantages of spatial methods for measuring therapeutic response 

12:00 pm Exploring the Regulatory Parameters of Digital Pathology in Precision Medicine to Guide Patient Selection & Protocol Design

Director - Global Regulatory Affairs, Precision Medicine Digital Health, GSK
  • Utilizing unique AI-powered digital pathology insights to inform patient stratification and selection
  • Integrating digital pathology early into trial design to safeguard clinical success downstream
  • Navigating device and software requirements for use of digital pathology in clinical trials

12:30 pm Lunch Break & Networking

Successfully Implementing Spatial Biology & Digital Pathology Across Therapeutic Pipelines with Optimized, Time & Cost-Effective Workflows

1:30 pm Optimizing Spatial Biology Techniques & Selecting Appropriate Technologies to Accelerate Discovery Efforts

Senior Scientist, BioMarin Pharmaceutical
  • Understanding the strengths, limitations, and ideal use cases of emerging spatial and single-cell platforms to ensure the right technology answers the right research question
  • Integrating tools, workflows, and collaborative approaches to streamline analysis and enable cost-effective implementation of spatial omics
  • Case study example of implementing an effective spatial omics analysis workflow to accurately answer research questions

2:00 pm Round Table Discussion: Transforming Therapeutic Pipelines with Appropriate Spatial Omics & Digital Pathology Workflows to Inform Discovery & Maximize Clinical Success

Vice President - Translational Medicine, BridgeBio Oncology Therapeutics
  • Evaluating technologies based on research goals and available resources to ensure the right tools are employed at the right stage for maximum efficiency and impact
  • Implementing spatial biology effectively into early R&D pipelines to unlock deeper understanding of pathology and target selection
  • Translating findings through to the clinic with digital pathology to enhance patient selection and biomarker validation

2:45 pm Afternoon Break & Scientific Poster Session

This is your opportunity to share your work with fellow members of the community, showcasing your therapeutic breakthroughs powered by spatial biology and digital pathology. *Please visit website for more details

Integrating Emerging Technologies for Digital Pathology to Optimize Biomarker Discovery, Patient Selection & Precision Medicine Pipelines

3:45 pm Advancing Clinical Development & Biomarker Validation with Next-Generation Digital Pathology Capabilities to Advance Precision Medicine

Director - Pathobiology, Gilead
  • Selecting appropriate AI tools, analytical workflows and instruments to streamline image analysis
  • Standardising data reporting and interpretation to ensure reliability across research projects
  • Converting large digital datasets into useful biomedical conclusions to inform biomarker validation and clinical development

4:15 pm Translating Precision Biomarkers into Clinical Trials with AI and Digital Pathology

Senior Director - Translational Pathology, Bristol Myers Squibb
  • Advancing translational biomarker discovery by integrating novel assays with AI-driven image analysis to bridge preclinical findings into proof-of-concept clinical testing.
  • Leveraging virtual IHC to increase efficiency in clinical trial biomarker evaluation by using H&E-based screening to rapidly identify the most informative biomarkers for PD/MoA studies and patient stratification.
  • Confirming and refining biomarkers for clinical use through targeted mIF/IHC validation of the top candidates, enabling the development of robust, trial-ready clinical assays.

4:45 pm Chair’s Closing Remarks

Vice President - Translational Medicine, BridgeBio Oncology Therapeutics

5:00 pm End of Conference Day One